- Home
- AMSF vs NEO Comparison
AMSF vs NEO Comparison
Compare AMSF & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- NEO
- Stock Information
- Founded
- AMSF 1985
- NEO 2001
- Country
- AMSF United States
- NEO United States
- Employees
- AMSF N/A
- NEO N/A
- Industry
- AMSF Accident &Health Insurance
- NEO Precision Instruments
- Sector
- AMSF Finance
- NEO Health Care
- Exchange
- AMSF Nasdaq
- NEO Nasdaq
- Market Cap
- AMSF 857.2M
- NEO 798.3M
- IPO Year
- AMSF 2005
- NEO 1999
- Fundamental
- Price
- AMSF $46.89
- NEO $6.61
- Analyst Decision
- AMSF Buy
- NEO Buy
- Analyst Count
- AMSF 2
- NEO 8
- Target Price
- AMSF $57.50
- NEO $12.00
- AVG Volume (30 Days)
- AMSF 105.8K
- NEO 3.0M
- Earning Date
- AMSF 07-24-2025
- NEO 07-29-2025
- Dividend Yield
- AMSF 9.87%
- NEO N/A
- EPS Growth
- AMSF N/A
- NEO N/A
- EPS
- AMSF 2.63
- NEO N/A
- Revenue
- AMSF $306,470,000.00
- NEO $689,189,000.00
- Revenue This Year
- AMSF $2.08
- NEO $13.83
- Revenue Next Year
- AMSF $4.93
- NEO $11.35
- P/E Ratio
- AMSF $17.83
- NEO N/A
- Revenue Growth
- AMSF N/A
- NEO 9.70
- 52 Week Low
- AMSF $42.48
- NEO $4.72
- 52 Week High
- AMSF $60.24
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- AMSF 62.64
- NEO 58.15
- Support Level
- AMSF $44.36
- NEO $5.94
- Resistance Level
- AMSF $46.21
- NEO $6.35
- Average True Range (ATR)
- AMSF 0.80
- NEO 0.26
- MACD
- AMSF 0.15
- NEO 0.12
- Stochastic Oscillator
- AMSF 92.39
- NEO 99.20
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.